HMGA1 overexpression is associated with a particular subset of human breast carcinomas

Journal of Clinical Pathology

Volumn 69, Issue 2, 2016, Pages 117-121

  Sepe, Romina ^a   Piscuoglio, Salvatore ^b,c   Quintavalle, Cristina ^b   Perrina, Valeria ^b   Quagliata, Luca ^b   Formisano, Umberto ^a   Terracciano, Luigi Maria ^b   Fusco, Alfredo ^a,d   Pallante, Pierlorenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HIGH MOBILITY GROUP A PROTEIN; HIGH MOBILITY GROUP A1 PROTEIN; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MICROARRAY KIT; PRIORITY JOURNAL; TISSUE MICROARRAY; BREAST NEOPLASMS; CANCER GRADING; CARCINOMA, DUCTAL, BREAST; CHEMISTRY; EVALUATION STUDY; FEMALE; GENE AMPLIFICATION; GENETICS; PATHOLOGY; PREDICTIVE VALUE; UPREGULATION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE AMPLIFICATION; HMGA PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84958107993     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2015-202907     Document Type: Article

References (35)

1. Ellis IO, Schnitt SJ, Sastre-Garau X, et al. Pathology and genetics of tumors of the breast and female genital organs. In: Tavassoli FA, Devilee P, eds. World Health Organization classification of tumours. Lyon, France: IARC Press, 2003:13-59.
2. Vogelstein B, Kinzler KW. Has the breast cancer gene been found? Cell 1994;79:1-3.
3. Miecznikowski JC, Wang D, Liu S, et al. Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. BMC Cancer 2010;10:573.
4. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006;116:561-70.
5. Gao X, Nawaz Z. Progesterone receptors - animal models and cell signaling in breast cancer: Role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. Breast Cancer Res 2002;4:182-6.
6. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
7. Koumoundourou D, Kassimatis T, Zolota V, et al. Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours. Anticancer Res 2007;27:2613-20.
8. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
9. Arteaga CL. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 2003;5:96-100.
10. Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin 2009;59:303-13.
11. Johnson KR, Lehn DA, Reeves R. Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 1989;9:2114-23.
12. Grosschedl R, Giese K, Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet 1994;10:94-100.
13. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992;71:777-89.
14. Fedele M, Fusco A. HMGA and cancer. Biochim Biophys Acta 2010;1799:48-54.
15. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439-46.
16. Zhou X, Benson KF, Ashar HR, et al. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-4.
17. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
18. Berlingieri MT, Pierantoni GM, Giancotti V, et al. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene 2002;21:2971-80.
19. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21:575-94.
20. Wood LJ, Maher JF, Bunton TE, et al. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60:4256-61.
21. Chiappetta G, Botti G, Monaco M, et al. HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res 2004;10:7637-44.
22. Baldassarre G, Battista S, Belletti B, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 2003;23:2225-38.
23. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast. 4th edn. IARC Press, 2012.
24. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
25. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997-4013.
26. Piscuoglio S, Ng CK, Martelotto LG, et al. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol 2014;8:1588-602.
27. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
28. Piscuoglio S, Zlobec I, Pallante P, et al. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology 2012;60:397-404.
29. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
30. Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 1997;57:4368-77.
31. Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
32. Cserni G, Francz M, Kalman E, et al. Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they? Pathol Oncol Res 2011;17:663-8.
33. Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-8.
34. Rhodes A, Jasani B. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact? J Clin Pathol 2009;62:95-6.
35. Yu KD, Di GH, Wu J, et al. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol 2008;134:1347-54.